Brief: Tiziana Life Sciences Announces University of Massachusetts Starts Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
23/04/2025 12:45
April 23 (Reuters) - Tiziana Life Sciences Ltd TLSA.O: TIZIANA LIFE SCIENCES ANNOUNCES UNIVERSITY OF MASSACHUSETTS COMMENCES DOSING INTRANASAL FORALUMAB IN PHASE 2 MULTIPLE SCLEROSIS TRIAL Source text: ID:nGNX5qmmkT Further company coverage: TLSA.O ((reuters.briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis